시장보고서
상품코드
1782020

세계의 액체생검 시장 : 샘플 유형별, 바이오마커별, 기술별, 제품별, 임상 응용별, 용도별, 최종 사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율 예측(2025-2032년)

Liquid Biopsy Market, By Sample Type, By Biomarker, By Technology, By Product, By Clinical Application, By Application, By End-User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 383 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

세계의 액체생검 시장 규모는 2024년 121억 2,424만 달러로, 2025년부터 2032년까지 연평균 복합 성장률(CAGR) 11.6%로 확대될 것으로 예상

액체생검 시장 - 시장 역학

암의 유병률 증가는 조기 스크리닝과 치료제 수요를 높여 시장 성장을 가속할 것으로 예측됩니다.

암이 세계적으로 이환율과 사망률의 주요 요인으로 부상함에 따라, 건강 관리 시스템은 악성 종양을 진행하기 전에 발견하기 위한 조기 진단을 점점 우선시하고 있습니다. 이러한 변화는 액체 생체생성, 영상 기술, 분자진단 평가와 같은 고급 스크리닝 기술의 이용을 촉진합니다. 미국 국립암 연구소는 2025년까지 미국에서 약 204만 1910명의 암 환자가 새롭게 확인되어 61만 8120명이 암으로 사망할 것으로 예측했습니다. 그 결과 조기 진단부터 치료까지 암 치료의 일련의 흐름은 증가하는 의료 수요에 대응하기 위해 급속히 진화하고 있으며, 조기 스크리닝 기기와 획기적인 치료제 모두 시장을 더욱 자극하고 있습니다. 또한, 유전체 기술과 분자 기술의 진보는 시장에 성장 기회를 가져올 수 있습니다. 그럼에도 불구하고 표준화 부족과 규제 장애물이 시장 확대를 방해할 수 있습니다.

액체생검 시장 - 주요 인사이트

당사의 리서치 애널리스트가 공유한 분석에 따르면, 세계 시장은 예측 기간(2025-2032년)에 약 11.6%의 연평균 복합 성장률(CAGR)로 매년 성장할 것으로 예측되고 있습니다.

샘플 유형별로는, 혈액 샘플이 2024년에 가장 큰 시장 점유율을 나타낼 것으로 예측됐습니다.

바이오마커별로는, 순환 종양 세포(CTC)가 2024년 주요 용도였습니다.

기술 세분화별로는, 다중 유전자 병렬 분석(NGS)이 2024년 주요 기술이었습니다.

제품 부문별로는 장비가 2024년 주요 제품이었습니다.

임상적 응용의 세분화에 기초하여, 2024년 주요 최종 사용자는 치료법 선택이었습니다.

용도별로 2024년 최종 사용자는 암이었습니다.

최종 사용자별로는 병원과 연구소가 2024년 주요 최종 사용자였습니다.

지역별로는 북미가 2024년에 수익을 창출하는 주요 시장이었습니다.

액체생검 시장 - 세분화 분석 :

세계의 액체생검 시장은 샘플 유형, 용도, 기술, 제품, 임상 응용, 응용, 최종 사용자, 지역에 따라 세분화됩니다.

시장은 표본 유형별로 혈액 샘플 및 기타 부문으로 분류됩니다. 혈액 샘플은 시장 성장의 주요 촉진요인입니다. 혈액 샘플은 주로 채취의 용이성, 낮은 침습성 및 환자의 컴플라이언스 수준의 높이로 인해 액체 생체 인식 분야를 지배합니다. 혈액 기반 액체생검은 순환 종양 DNA(ctDNA), 순환 종양 세포(CTC) 및 기타 다양한 바이오마커의 검출 및 분석을 용이하게 하며, 종양 유전자 프로파일의 완전한 개요를 실시간으로 제공합니다. 조직 생검에 비해 혈액 샘플은 암 진단, 예후, 치료 모니터링, 조기 발견에 보다 빠르고 안전하며 경제적인 옵션을 제공합니다. 병원, 진단센터 및 연구 기관이 혈액 기반 검사를 광범위하게 채택하는 것은 시장에서 주도적 지위를 더욱 강화하고 있습니다.

시장은 바이오마커별로 순환 종양 세포(CTC), 순환 종양 DNA(ctDNA), 세포 외 차량(EV) 등의 부문으로 분류됩니다. 순환 종양 세포(CTC)는 시장 성장을 이끌고 있습니다. CTC는 암의 진단, 예후, 치료 모니터링에 중요한 역할을 하기 때문에 액체생검 시장의 성장 촉진요인이 되고 있습니다. CTC는 원발성 종양과 전이성 종양으로부터 분리하여 혈류로 이동하는 암세포이며, 종양의 불균일성과 전이 가능성에 대한 본질적인 통찰력을 제공합니다. 침습적인 치료를 필요로 하지 않고, 질환의 진행이나 치료 반응에 관한 데이터를 실시간으로 제공할 수 있기 때문에 종양학에 있어서 바람직한 바이오마커로 되어 있습니다.

시장은 기술별로 다유전자 병렬 분석(NGS) 및 단일 유전자 분석(PCR 마이크로어레이) 부문으로 분류됩니다. 다유전자 병렬 분석(NGS)는 시장 성장의 주요 촉진요인입니다. 차세대 시퀀서(NGS)를 이용한 다유전자 병렬 분석은 탁월한 감도와 특이성으로 여러 유전자 변화를 동시에 평가할 수 있기 때문에 액체생검 시장의 성장으로 이어집니다. NGS는 소량의 샘플로부터 광범위한 유전체 프로파일링을 용이하게 하고, 종양 생물학, 돌연변이 부하 및 잠재적인 치료 표적에 대한 상세한 통찰을 임상의에게 제공합니다. 이 방법은 드문 돌연변이 및 내성 메커니즘을 실시간으로 확인할 수 있기 때문에 맞춤형 의료에 특히 유용합니다. 암의 조기 발견, 치료법의 선택, 미소잔존 병변의 모니터링을 위해, 암 영역에서 NGS 기반의 액체생검 패널의 도입이 증가하고 있는 것이 시장 성장을 크게 뒷받침하고 있습니다.

시장은 제품별로 장비, 소모품 키트 및 시약, 소프트웨어 및 서비스 유형으로 분할됩니다. 시장의 성장을 선도하는 것은 장비입니다. 순환종양세포(CTC), 순환종양 DNA(ctDNA), 엑소좀 등의 순환 바이오마커를 정확하게 동정·분석할 수 있는 첨단 기술에 대한 수요가 높아지면서 액체생검 시장 확대의 최전선에 있는 것은 기기입니다. NGS 플랫폼, PCR 시스템, 마이크로플루이딕스 장치 및 자동 액체 처리 시스템을 포함한 이러한 장비는 진단 프로세스에서 높은 처리량, 고감도 및 고정밀도를 달성하는 데 필수적입니다. 종양학 애플리케이션을 위해 설계된 혁신적이고 사용하기 쉬운 통합 시스템의 발전이 계속됨에 따라 병원, 진단 실험실 및 연구 기관에서의 채용이 가속화되고 있습니다.

시장은 임상 응용별로 치료법 선택, 치료 모니터링, 조기 암 스크리닝, 재발 모니터링 등의 부문으로 분류됩니다. 치료법 선택은 시장 성장의 주요 촉진요인입니다. 순환 종양 DNA(ctDNA) 또는 다른 바이오마커를 조사함으로써, 액체생검는 침습적인 조직 채취를 필요로 하지 않고 특정 돌연변이, 유전자 융합, 내성 메커니즘의 검출을 용이하게 합니다. 이 방법을 통해 암 전문의는 환자의 명확한 분자 프로파일에 따라 표적 치료 및 면역 요법과 같은 치료를 사용자 정의 할 수 있으므로 임상 결과를 향상시키고 불필요한 독성을 줄일 수 있습니다. 정밀의료에 대한 주목의 높아짐과, 치료중의 종양의 동적 변화를 추적하는 액체생검의 능력이 함께, 다양한 암종에 있어서의 치료법의 선택에 있어서 액체생검가 완수하는 중요한 역할이 한층 더 강화되고 있습니다.

시장은 용도별로 암, 생식 의료, 폐암, 전립선암, 유방암, 대장암, 백혈병, 소화기 암, 기타 부문으로 분류됩니다. 암 분야는 시장 성장의 최전선에 있습니다. 액체생검 분야에서는 다양한 암의 세계적 유병률 증가와 비침습적 진단법에 대한 수요 증가에 힘입어 암 분야가 시장 확대를 견인하고 있습니다. 액체생검은 체액(주로 혈액) 유래의 ctDNA, CTC, 엑소좀 등의 바이오마커를 조사함으로써 암의 조기 발견, 종양 프로파일링, 치료 모니터링, 재발 예측을 위한 획기적인 방법을 제공합니다. 기존의 조직 생검에 비해 리스크의 저감, 신속한 납기, 종양의 불균일성을 파악하는 능력 등의 이점이 있기 때문에 종양학에 있어서 필수적인 기기로서 확립하고 있습니다. 정밀의료가 암 치료에 필수적이 됨에 따라 폐암, 유방암, 대장암, 전립선암 등 고형암 관리에 있어서의 액체생검의 응용은 지속적으로 확대되고 있으며, 이 분야의 진보를 더욱 뒷받침하고 있습니다.

시장은 최종 사용자별로 병원 및 연구소, 전문 클리닉, 학술 및 연구센터, 기타 부문으로 분류됩니다. 병원 및 연구소 부문은 시장 성장의 최전선에 있습니다. 이 부문은 첨단 진단 기술의 채택이 증가하고 이러한 환경에서 실시되는 암 스크리닝 및 모니터링의 수가 증가하고 있기 때문에 액체생검 산업의 확대를 견인하고 있습니다. 병원과 임상 실험실은 진단 평가를 받는 환자의 첫 접점이 되는 경우가 많으며, 액체생검 검사의 전개에 필수적인 센터가 되고 있습니다. 이러한 시설은 숙련된 전문가의 존재, 확립된 인프라, NGS 및 PCR 플랫폼과 같은 높은 처리량 장비에 대한 액세스로 이점을 얻습니다.

액체생검 시장 - 지리적 통찰

북미가 시장 성장에 선도하고 있는 것은 견조한 연구개발과 견실한 상환의 틀에 의한 것입니다. 이 지역의 정교한 헬스케어 시스템, 조기암 검진에 대한 의식의 높아짐, 학술기관과 업계 이해 관계자의 강력한 파트너십은 북미가 세계의 액체생검 시장에서 완수하는 역할을 더욱 견고하게 하고 있습니다. 미국 의사회의 보고서에 따르면 미국은 2023년 건강 관리에 4조 8,665억 달러를 할당했습니다. 유럽은 또한 암에 대한 의식이 높아지고 건강 관리에 대한 접근이 강화되고 조기 발견 이니셔티브에 대한 정부의 자금 지원에 힘입어 시장의 상당 부분을 차지하고 있습니다.

액체생검 시장 - 경쟁 구도 :

액체생검 시장은 치열한 경쟁과 끊임없는 진화를 특징으로 하며, 다수의 기존 기업과 신규 참가 기업이 기술 혁신, 제휴, 성장 전략을 통해 경쟁 우위를 확보하려고 하고 있습니다. 각 회사는 차세대 시퀀싱(NGS), 액적 디지털 PCR, 다유전자 패널 검사 등의 첨단 기술을 바탕으로 경쟁력이 있어 리퀴드 생검 분석의 민감도, 특이성 및 속도를 향상시킵니다. 주요 기업은 아시아태평양과 라틴아메리카의 신흥 시장에 중점을두고 미개척의 기회를 포착하기 위해 지역 자회사와 판매망을 설립하고 있습니다.

목차

제1장 액체생검 시장 개요

  • 조사 범위
  • 시장 추정 연도

제2장 주요 요약

  • 시장 분석
  • 경쟁 인사이트

제3장 액체생검 주요 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 시장의 미래 동향

제4장 액체생검 산업 연구

  • PEST 분석
  • Porter's Five Forces 분석
  • 성장 전망 맵핑
  • 규제 틀 분석

제5장 액체생검 시장 : 높아지는 지정학적 긴장의 영향

  • COVID-19 팬데믹의 영향
  • 러시아 및 우크라이나 전쟁의 영향
  • 중동 분쟁의 영향

제6장 액체생검 시장 상황

  • 액체생검 시장 점유율 분석, 2024년
  • 주요 제조업체별 분석 데이터
    • 기존 기업의 분석
    • 신흥 기업의 분석

제7장 액체생검 시장 - 샘플 유형별

  • 개요
    • 샘플 유형별 부문 점유율 분석
    • 혈액 샘플
    • 기타

제8장 액체생검 시장 - 바이오마커별

  • 개요
    • 바이오마커별 부문 점유율 분석
    • 순환 종양 세포(CTC)
    • 순환 종양 DNA(ctDNA)
    • 세포외소포(EV)
    • 기타

제9장 액체생검 시장 - 기술별

  • 개요
    • 기술별 부문 점유율 분석
    • 다중 유전자 병렬 분석(NGS)
    • 단일 유전자 분석(PCR 마이크로어레이)

제10장 액체생검 시장 - 제품별

  • 개요
    • 제품별 부문 점유율 분석
    • 기기
    • 소모품 키트 및 시약
    • 소프트웨어 및 서비스

제11장 액체생검 시장 - 임상 용도별

  • 개요
    • 임상 응용별 부문 점유율 분석
    • 치료법 선택
    • 치료 모니터링
    • 조기암 검진
    • 재발 모니터링
    • 기타

제12장 액체생검 시장 - 용도별

  • 개요
    • 용도별 부문 점유율 분석
    • 생식보건
    • 폐암
    • 전립선암
    • 유방암
    • 대장암
    • 백혈병
    • 소화기 암
    • 기타

제13장 액체생검 시장 - 최종 사용자별

  • 개요
    • 최종 사용자별 부문 점유율 분석
    • 병원 및 연구소
    • 전문 클리닉
    • 학술연구센터
    • 기타

제14장 액체생검 시장 - 지역별

  • 소개
  • 북미
    • 개요
    • 북미의 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 개요
    • 유럽의 주요 제조업체
    • 독일
    • 영국
    • 프랑스
    • 이탈리아
    • 스페인
    • 네덜란드
    • 스웨덴
    • 러시아
    • 폴란드
    • 기타
  • 아시아태평양(APAC)
    • 개요
    • 아시아태평양의 주요 제조업체
    • 중국
    • 인도
    • 일본
    • 한국
    • 호주
    • 인도네시아
    • 태국
    • 필리핀
    • 기타
  • 라틴아메리카(LATAM)
    • 개요
    • 라틴아메리카의 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카
    • 개요
    • 중동 및 아프리카의 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 튀르키예
    • 알제리
    • 이집트
    • 기타

제15장 주요 벤더 분석 - 액체생검 업계

  • 경쟁 대시보드
    • 경쟁 벤치마킹
    • 경쟁 포지셔닝
  • 기업 프로파일
    • Guardant Health, Inc.
    • Foundation Medicine, Inc.(Roche subsidiary)
    • Illumina, Inc.
    • GRAIL, Inc.(subsidiary of Illumina)
    • Bio-Rad Laboratories, Inc.
    • Exact Sciences Corporation
    • Thermo Fisher Scientific Inc.
    • Natera, Inc.
    • Freenome Holdings, Inc.
    • QIAGEN NV
    • Lucence Diagnostics
    • Inivata Ltd.(NeoGenomics subsidiary)
    • Angle plc
    • Sysmex Corporation
    • Biocept, Inc.
    • Oncocyte Corporation
    • Personal Genome Diagnostics(PGDx)
    • Chronix Biomedical
    • Epic Sciences, Inc.
    • Cynvenio Biosystems, Inc.
    • Others

제16장 애널리스트의 전방위 전망

JHS 25.08.11

REPORT HIGHLIGHT

Liquid Biopsy Market size was valued at US$ 12,124.24 Million in 2024, expanding at a CAGR of 11.6% from 2025 to 2032.

A liquid biopsy is a non-invasive diagnostic procedure that evaluates bodily fluids, mainly blood, to identify cancer or other illnesses. It analyzes biomarkers such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) to detect genetic or molecular alterations linked to a tumor. Liquid biopsies can facilitate early cancer detection, monitor the effectiveness of treatments, and evaluate tumor progression. Much of the initial research on liquid biopsies has focused on lung, breast, and prostate cancers; however, this technology is anticipated to influence all cancer types. Liquid biopsy represents a relatively recent testing method with numerous potential revolutionary applications in cancer therapy, including several uses that have received approval from the U.S. Food and Drug Administration (FDA). Ongoing research continues to explore its advantages.

Liquid Biopsy Market- Market Dynamics

The increasing prevalence of cancer is anticipated to boost the demand for early screening and therapeutics, thereby driving market growth.

As cancer emerges as a primary contributor to morbidity and mortality globally, healthcare systems are increasingly prioritizing early-stage diagnostics to detect malignancies before their advancement. This shift is propelling the utilization of sophisticated screening technologies, including liquid biopsies, imaging techniques, and molecular diagnostic assessments. The National Cancer Institute projects that by 2025, approximately 2,041,910 new cancer cases will be identified in the United States, with 618,120 fatalities attributed to the disease. Consequently, the cancer care continuum, encompassing early diagnosis through to treatment, is rapidly evolving to address the escalating healthcare demands, thereby further stimulating the market for both early screening instruments and groundbreaking therapeutics. Additionally, advancements in genomic and molecular technologies may present growth opportunities for the market. Nevertheless, the lack of standardization and regulatory hurdles could impede market expansion.

Liquid Biopsy Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 11.6% over the forecast period (2025-2032)

Based on the Sample Type segmentation, the Blood Sample was predicted to show maximum market share in the year 2024

Based on Biomarker segmentation, Circulating Tumor Cells (CTCs) were the leading application in 2024

Based on Technology segmentation, Multi-gene-parallel Analysis (NGS) was the leading Technology in 2024

Based on Product segmentation, Instruments were the leading Product in 2024

Based on Clinical application segmentation, Therapy Selection was the leading End-User in 2024

Based on Application segmentation, Cancer was the leading End-User in 2024

Based on End-User segmentation, Hospitals and Laboratories were the leading End-User in 2024

Based on region, North America was the leading revenue generator in 2024

Liquid Biopsy Market- Segmentation Analysis:

The Global Liquid Biopsy Market is segmented based on Sample Type, Application, Technology, Product, Clinical Application, Application, End-User, and Region.

The market is categorized into three segments according to Sample Type: Blood Sample and Others. Blood Sample is the primary driver of market growth. Blood samples dominate the Liquid Biopsy sector, mainly due to their ease of collection, low invasiveness, and high levels of patient compliance. Blood-based liquid biopsies facilitate the detection and analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and various other biomarkers, providing a thorough overview of the tumor's genetic profile in real-time. In comparison to tissue biopsies, blood samples offer a quicker, safer, and more economical option for cancer diagnosis, prognosis, treatment monitoring, and early detection. The extensive adoption of blood-based tests by hospitals, diagnostic centers, and research institutions further reinforces their leading position in the market.

The market is categorized into three segments based on biomarkers: Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), and Extracellular Vehicles (EVs), among others. Circulating Tumor Cells (CTCs) lead the growth of the market. CTCs are the primary drivers of growth in the Liquid Biopsy market, due to their significant role in cancer diagnosis, prognosis, and treatment monitoring. CTCs are cancer cells that separate from primary or metastatic tumors and travel through the bloodstream, providing essential insights into tumor heterogeneity and metastatic potential. Their capacity to deliver real-time data on disease progression and treatment response without requiring invasive procedures renders them a preferred biomarker in oncology.

The market is categorized into two segments based on technology: Multi-gene-parallel Analysis (NGS) and Single Gene Analysis (PCR Microarrays). Multi-gene-parallel Analysis (NGS) is the primary driver of market growth. The multi-gene parallel analysis utilising Next-Generation Sequencing (NGS) leads to the growth of the Liquid Biopsy market, owing to its capability to concurrently assess multiple genetic alterations with exceptional sensitivity and specificity. NGS facilitates extensive genomic profiling from small sample volumes, equipping clinicians with in-depth insights into tumor biology, mutation load, and possible therapeutic targets. This methodology is particularly beneficial for personalized medicine, as it enables the identification of rare mutations and resistance mechanisms in real time. The rising implementation of NGS-based liquid biopsy panels in oncology for early cancer detection, treatment selection, and monitoring of minimal residual disease is greatly enhancing the market's growth.

The market is segmented into three categories based on Product: Instruments, Consumables Kits and Reagents, and Software and Services. Instruments lead the growth of the market. Instruments are at the forefront of the Liquid Biopsy market expansion, propelled by the rising demand for sophisticated technologies that can accurately identify and analyze circulating biomarkers such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes. These instruments, which include NGS platforms, PCR systems, microfluidic devices, and automated liquid handling systems, are crucial for achieving high throughput, sensitivity, and precision in diagnostic processes. The ongoing advancement of innovative, user-friendly, and integrated systems designed for oncology applications has accelerated their adoption in hospitals, diagnostic laboratories, and research institutions.

The market is categorized into four segments based on Clinical Application: Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring, and Others. Therapy Selection is the primary driver of market growth. By examining circulating tumor DNA (ctDNA) or other biomarkers, liquid biopsy facilitates the detection of specific mutations, gene fusions, and resistance mechanisms without requiring invasive tissue sampling. This method enables oncologists to customize therapies such as targeted treatments or immunotherapies according to a patient's distinct molecular profile, thereby enhancing clinical outcomes and reducing unnecessary toxicity. The increasing focus on precision medicine, coupled with the capability of liquid biopsy to track dynamic tumor alterations during treatment, further reinforces its essential role in therapy selection across different cancer types.

The market is categorized into eight segments based on application: Cancer, Reproductive Health, Lung Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Gastrointestinal Cancer, and Others. The cancer segment is at the forefront of market growth. In the Liquid Biopsy sector, the cancer segment is driving market expansion, propelled by the increasing global prevalence of various cancers and the rising demand for non-invasive diagnostic methods. Liquid biopsy provides a revolutionary method for the early detection of cancer, tumor profiling, treatment monitoring, and predicting relapses by examining biomarkers such as ctDNA, CTCs, and exosomes derived from body fluids-mainly blood. Its benefits over conventional tissue biopsies, which include reduced risk, faster turnaround times, and the capacity to capture tumor heterogeneity, have established it as an essential instrument in oncology. As precision medicine becomes more integral to cancer treatment, the application of liquid biopsy in the management of solid tumors like lung, breast, colorectal, and prostate cancer is continually growing, further propelling the advancement of this segment.

The market is categorized into four segments based on End-User: Hospitals and Laboratories, Specialty Clinics, Academic and Research Centers, and Others. The Hospitals and Laboratories segment is at the forefront of market growth. This segment is driving the expansion of the Liquid Biopsy industry due to the increasing adoption of advanced diagnostic technologies and the growing number of cancer screening and monitoring procedures conducted in these environments. Hospitals and clinical laboratories frequently serve as the initial point of contact for patients undergoing diagnostic assessments, rendering them essential centers for the deployment of liquid biopsy tests. These institutions gain advantages from the presence of skilled professionals, established infrastructure, and access to high-throughput instruments such as NGS and PCR platforms.

Liquid Biopsy Market- Geographical Insights

North America leads in market growth, attributed to robust research and development as well as a solid reimbursement framework. The region's sophisticated healthcare system heightened awareness regarding early cancer screening, and strong partnerships between academic institutions and industry stakeholders further solidify North America's prominent role in the global liquid biopsy market. As reported by the American Medical Association, the United States allocated USD 4,866.5 billion for healthcare in 2023. Europe also orders a substantial portion of the market, bolstered by increasing cancer awareness, enhanced access to healthcare, and government funding for early detection initiatives.

Liquid Biopsy Market- Competitive Landscape:

The liquid biopsy market is characterized by intense competition and constant evolution, with numerous established and new entrants seeking to secure a competitive advantage through innovation, collaborations, and growth strategies. Firms are competing based on cutting-edge technologies such as next-generation sequencing (NGS), droplet digital PCR, and multi-gene panel testing to enhance the sensitivity, specificity, and speed of liquid biopsy assays. Leading companies are placing greater emphasis on emerging markets in the Asia Pacific and Latin America by setting up regional subsidiaries and distribution networks to seize untapped opportunities.

Recent Developments:

On November 1, 2023, Illumina Inc., a worldwide frontrunner in DNA sequencing and array-based technologies, announced the launch of a new generation of its distributed liquid biopsy assay designed for genomic profiling. The latest TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay that facilitates noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) extracted from blood samples when tissue testing is not feasible, or enhances tissue-based testing.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL LIQUID BIOPSY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Guardant Health, Inc.
  • Foundation Medicine, Inc. (Roche subsidiary)
  • Illumina, Inc.
  • GRAIL, Inc. (a subsidiary of Illumina)
  • Bio-Rad Laboratories, Inc.
  • Exact Sciences Corporation
  • Thermo Fisher Scientific Inc.
  • Natera, Inc.
  • Freenome Holdings, Inc.
  • QIAGEN N.V.
  • Lucence Diagnostics
  • Inivata Ltd. (NeoGenomics subsidiary)
  • Angle plc
  • Sysmex Corporation
  • Biocept, Inc.
  • Oncocyte Corporation
  • Personal Genome Diagnostics (PGDx)
  • Chronix Biomedical
  • Epic Sciences, Inc.
  • Cynvenio Biosystems, Inc.
  • Others

GLOBAL LIQUID BIOPSY MARKET, BY SAMPLE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Blood Sample
  • Others

GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER- MARKET ANALYSIS, 2019 - 2032

  • Circulating Tumor Cells (CTCs)
  • Circulating Tumor DNA (ctDNA)
  • Extracellular Vehicles (EVs)
  • Others

GLOBAL LIQUID BIOPSY MARKET, BY TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032

  • Multi-gene-parallel Analysis (NGS)
  • Single Gene Analysis (PCR Microarrays)

GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT- MARKET ANALYSIS, 2019 - 2032

  • Instruments
  • Consumables Kits and Reagents
  • Software and Services

GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Therapy Selection
  • Treatment Monitoring
  • Early Cancer Screening
  • Recurrence Monitoring
  • Others

GLOBAL LIQUID BIOPSY MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Cancer
  • Reproductive Health
  • Lung Cancer
  • Prostate Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Gastrointestinal Cancer
  • Others

GLOBAL LIQUID BIOPSY MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals and Laboratories
  • Specialty Clinics
  • Academic and Research Centers
  • Others

GLOBAL LIQUID BIOPSY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Liquid Biopsy Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Liquid Biopsy Market Snippet by Sample Type
    • 2.1.2. Liquid Biopsy Market Snippet by Biomarker
    • 2.1.3. Liquid Biopsy Market Snippet by Technology
    • 2.1.4. Liquid Biopsy Market Snippet by Product
    • 2.1.5. Liquid Biopsy Market Snippet by Clinical Application
    • 2.1.6. Liquid Biopsy Market Snippet by Application
    • 2.1.7. Liquid Biopsy Market Snippet by End-User
    • 2.1.8. Liquid Biopsy Market Snippet by Country
    • 2.1.9. Liquid Biopsy Market Snippet by Region
  • 2.2. Competitive Insights

3. Liquid Biopsy Key Market Trends

  • 3.1. Liquid Biopsy Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Liquid Biopsy Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Liquid Biopsy Market Opportunities
  • 3.4. Liquid Biopsy Market Future Trends

4. Liquid Biopsy Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Liquid Biopsy Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Liquid Biopsy Market Landscape

  • 6.1. Liquid Biopsy Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Liquid Biopsy Market - By Sample Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Sample Type, 2024 & 2032 (%)
    • 7.1.2. Blood Sample
    • 7.1.3. Others

8. Liquid Biopsy Market - By Biomarker

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Biomarker, 2024 & 2032 (%)
    • 8.1.2. Circulating Tumor Cells (CTCs)
    • 8.1.3. Circulating Tumor DNA (ctDNA)
    • 8.1.4. Extracellular Vehicles (EVs)
    • 8.1.5. Others

9. Liquid Biopsy Market - By Technology

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Technology, 2024 & 2032 (%)
    • 9.1.2. Multi-gene-parallel Analysis (NGS)
    • 9.1.3. Single Gene Analysis (PCR Microarrays)

10. Liquid Biopsy Market - By Product

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Product, 2024 & 2032 (%)
    • 10.1.2. Instruments
    • 10.1.3. Consumables Kits and Reagents
    • 10.1.4. Software and Services

11. Liquid Biopsy Market - By Clinical Application

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Clinical Application, 2024 & 2032 (%)
    • 11.1.2. Therapy Selection
    • 11.1.3. Treatment Monitoring
    • 11.1.4. Early Cancer Screening
    • 11.1.5. Recurrence Monitoring
    • 11.1.6. Others

12. Liquid Biopsy Market - By Application

  • 12.1. Overview
    • 12.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 12.1.2. Cancer
    • 12.1.3. Reproductive Health
    • 12.1.4. Lung Cancer
    • 12.1.5. Prostate Cancer
    • 12.1.6. Breast Cancer
    • 12.1.7. Colorectal Cancer
    • 12.1.8. Leukemia
    • 12.1.9. Gastrointestinal Cancer
    • 12.1.10. Others

13. Liquid Biopsy Market - By End-User

  • 13.1. Overview
    • 13.1.1. Segment Share Analysis, By End-User, 2024 & 2032 (%)
    • 13.1.2. Hospitals and Laboratories
    • 13.1.3. Specialty Clinics
    • 13.1.4. Academic and Research Centers
    • 13.1.5. Others

14. Liquid Biopsy Market- By Geography

  • 14.1. Introduction
    • 14.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 14.2. North America
    • 14.2.1. Overview
    • 14.2.2. Liquid Biopsy Key Manufacturers in North America
    • 14.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.2.4. North America Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 14.2.5. North America Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
    • 14.2.6. North America Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 14.2.7. North America Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 14.2.8. North America Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
    • 14.2.9. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 14.2.10. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.2.11. U.S.
      • 14.2.11.1. Overview
      • 14.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.2.11.3. U.S. Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.2.11.4. U.S. Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.2.11.5. U.S. Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.2.11.6. U.S. Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.2.11.7. U.S. Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.2.11.8. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.2.11.9. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.2.12. Canada
      • 14.2.12.1. Overview
      • 14.2.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.2.12.3. Canada Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.2.12.4. Canada Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.2.12.5. Canada Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.2.12.6. Canada Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.2.12.7. Canada Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.2.12.8. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.2.12.9. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 14.3. Europe
    • 14.3.1. Overview
    • 14.3.2. Liquid Biopsy Key Manufacturers in Europe
    • 14.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.3.4. Europe Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 14.3.5. Europe Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
    • 14.3.6. Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 14.3.7. Europe Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 14.3.8. Europe Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
    • 14.3.9. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 14.3.10. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.11. Germany
      • 14.3.11.1. Overview
      • 14.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.11.3. Germany Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.11.4. Germany Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.11.5. Germany Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.11.6. Germany Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.11.7. Germany Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.11.8. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.11.9. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.12. UK
      • 14.3.12.1. Overview
      • 14.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.12.3. UK Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.12.4. UK Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.12.5. UK Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.12.6. UK Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.12.7. UK Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.12.8. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.12.9. UK Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.13. France
      • 14.3.13.1. Overview
      • 14.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.13.3. France Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.13.4. France Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.13.5. France Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.13.6. France Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.13.7. France Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.13.8. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.13.9. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.14. Italy
      • 14.3.14.1. Overview
      • 14.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.14.3. Italy Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.14.4. Italy Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.14.5. Italy Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.14.6. Italy Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.14.7. Italy Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.14.8. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.14.9. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.15. Spain
      • 14.3.15.1. Overview
      • 14.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.15.3. Spain Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.15.4. Spain Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.15.5. Spain Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.15.6. Spain Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.15.7. Spain Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.15.8. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.15.9. Spain Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.16. The Netherlands
      • 14.3.16.1. Overview
      • 14.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.16.3. The Netherlands Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.16.4. The Netherlands Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.16.5. The Netherlands Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.16.6. The Netherlands Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.16.7. The Netherlands Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.16.8. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.16.9. The Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.17. Sweden
      • 14.3.17.1. Overview
      • 14.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.17.3. Sweden Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.17.4. Sweden Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.17.5. Sweden Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.17.6. Sweden Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.17.7. Sweden Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.17.8. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.17.9. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.18. Russia
      • 14.3.18.1. Overview
      • 14.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.18.3. Russia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.18.4. Russia Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.18.5. Russia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.18.6. Russia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.18.7. Russia Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.18.8. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.18.9. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.19. Poland
      • 14.3.19.1. Overview
      • 14.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.19.3. Poland Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.19.4. Poland Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.19.5. Poland Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.19.6. Poland Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.19.7. Poland Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.19.8. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.19.9. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.20. Rest of Europe
      • 14.3.20.1. Overview
      • 14.3.20.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.20.3. Rest of the Europe Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.20.4. Rest of the Europe Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.20.5. Rest of the Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.20.6. Rest of the Europe Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.20.7. Rest of the Europe Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.20.8. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.20.9. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 14.4. Asia Pacific (APAC)
    • 14.4.1. Overview
    • 14.4.2. Liquid Biopsy Key Manufacturers in Asia Pacific
    • 14.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.4.4. APAC Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 14.4.5. APAC Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
    • 14.4.6. APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 14.4.7. APAC Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 14.4.8. APAC Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
    • 14.4.9. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 14.4.10. APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.11. China
      • 14.4.11.1. Overview
      • 14.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.11.3. China Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.11.4. China Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.11.5. China Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.11.6. China Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.11.7. China Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.11.8. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.11.9. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.12. India
      • 14.4.12.1. Overview
      • 14.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.12.3. India Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.12.4. India Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.12.5. India Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.12.6. India Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.12.7. India Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.12.8. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.12.9. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.13. Japan
      • 14.4.13.1. Overview
      • 14.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.13.3. Japan Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.13.4. Japan Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.13.5. Japan Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.13.6. Japan Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.13.7. Japan Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.13.8. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.13.9. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.14. South Korea
      • 14.4.14.1. Overview
      • 14.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.14.3. South Korea Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.14.4. South Korea Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.14.5. South Korea Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.14.6. South Korea Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.14.7. South Korea Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.14.8. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.14.9. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.15. Australia
      • 14.4.15.1. Overview
      • 14.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.15.3. Australia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.15.4. Australia Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.15.5. Australia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.15.6. Australia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.15.7. Australia Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.15.8. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.15.9. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.16. Indonesia
      • 14.4.16.1. Overview
      • 14.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.16.3. Indonesia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.16.4. Indonesia Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.16.5. Indonesia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.16.6. Indonesia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.16.7. Indonesia Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.16.8. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.16.9. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.17. Thailand
      • 14.4.17.1. Overview
      • 14.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.17.3. Thailand Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.17.4. Thailand Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.17.5. Thailand Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.17.6. Thailand Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.17.7. Thailand Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.17.8. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.17.9. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.18. Philippines
      • 14.4.18.1. Overview
      • 14.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.18.3. Philippines Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.18.4. Philippines Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.18.5. Philippines Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.18.6. Philippines Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.18.7. Philippines Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.18.8. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.18.9. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.19. Rest of APAC
      • 14.4.19.1. Overview
      • 14.4.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.19.3. Rest of APAC Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.19.4. Rest of APAC Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.19.5. Rest of APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.19.6. Rest of APAC Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.19.7. Rest of APAC Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.19.8. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.19.9. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 14.5. Latin America (LATAM)
    • 14.5.1. Overview
    • 14.5.2. Liquid Biopsy Key Manufacturers in Latin America
    • 14.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.5.4. LATAM Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 14.5.5. LATAM Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
    • 14.5.6. LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 14.5.7. LATAM Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 14.5.8. LATAM Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
    • 14.5.9. LATAM Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 14.5.10. LATAM Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.5.11. Brazil
      • 14.5.11.1. Overview
      • 14.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.11.3. Brazil Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.5.11.4. Brazil Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.5.11.5. Brazil Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.5.11.6. Brazil Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.5.11.7. Brazil Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.5.11.8. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.5.11.9. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.5.12. Mexico
      • 14.5.12.1. Overview
      • 14.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.12.3. Mexico Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.5.12.4. Mexico Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.5.12.5. Mexico Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.5.12.6. Mexico Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.5.12.7. Mexico Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.5.12.8. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.5.12.9. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.5.13. Argentina
      • 14.5.13.1. Overview
      • 14.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.13.3. Argentina Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.5.13.4. Argentina Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.5.13.5. Argentina Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.5.13.6. Argentina Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.5.13.7. Argentina Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.5.13.8. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.5.13.9. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.5.14. Colombia
      • 14.5.14.1. Overview
      • 14.5.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.14.3. Colombia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.5.14.4. Colombia Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.5.14.5. Colombia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.5.14.6. Colombia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.5.14.7. Colombia Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.5.14.8. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.5.14.9. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.5.15. Rest of LATAM
      • 14.5.15.1. Overview
      • 14.5.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.15.3. Rest of LATAM Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.5.15.4. Rest of LATAM Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.5.15.5. Rest of LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.5.15.6. Rest of LATAM Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.5.15.7. Rest of LATAM Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.5.15.8. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.5.15.9. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 14.6. Middle East and Africa
    • 14.6.1. Overview
    • 14.6.2. Liquid Biopsy Key Manufacturers in Middle East and Africa
    • 14.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.6.4. Middle East and Africa Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 14.6.5. Middle East and Africa Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
    • 14.6.6. Middle East and Africa Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 14.6.7. Middle East and Africa Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 14.6.8. Middle East and Africa Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
    • 14.6.9. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 14.6.10. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.6.11. Saudi Arabia
      • 14.6.11.1. Overview
      • 14.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.11.3. Saudi Arabia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.6.11.4. Saudi Arabia Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.6.11.5. Saudi Arabia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.6.11.6. Saudi Arabia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.6.11.7. Saudi Arabia Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.6.11.8. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.6.11.9. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.6.12. United Arab Emirates
      • 14.6.12.1. Overview
      • 14.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.12.3. United Arab Emirates Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.6.12.4. United Arab Emirates Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.6.12.5. United Arab Emirates Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.6.12.6. United Arab Emirates Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.6.12.7. United Arab Emirates Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.6.12.8. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.6.12.9. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.6.13. Israel
      • 14.6.13.1. Overview
      • 14.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.13.3. Israel Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.6.13.4. Israel Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.6.13.5. Israel Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.6.13.6. Israel Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.6.13.7. Israel Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.6.13.8. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.6.13.9. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.6.14. Turkey
      • 14.6.14.1. Overview
      • 14.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.14.3. Turkey Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.6.14.4. Turkey Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.6.14.5. Turkey Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.6.14.6. Turkey Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.6.14.7. Turkey Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.6.14.8. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.6.14.9. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.6.15. Algeria
      • 14.6.15.1. Overview
      • 14.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.15.3. Algeria Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.6.15.4. Algeria Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.6.15.5. Algeria Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.6.15.6. Algeria Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.6.15.7. Algeria Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.6.15.8. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.6.15.9. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.6.16. Egypt
      • 14.6.16.1. Overview
      • 14.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.16.3. Egypt Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.6.16.4. Egypt Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.6.16.5. Egypt Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.6.16.6. Egypt Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.6.16.7. Egypt Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.6.16.8. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.6.16.9. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.6.17. Rest of MEA
      • 14.6.17.1. Overview
      • 14.6.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.17.3. Rest of MEA Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.6.17.4. Rest of MEA Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.6.17.5. Rest of MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.6.17.6. Rest of MEA Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.6.17.7. Rest of MEA Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.6.17.8. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.6.17.9. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

15. Key Vendor Analysis- Liquid Biopsy Industry

  • 15.1. Competitive Dashboard
    • 15.1.1. Competitive Benchmarking
    • 15.1.2. Competitive Positioning
  • 15.2. Company Profiles
    • 15.2.1. Guardant Health, Inc.
    • 15.2.2. Foundation Medicine, Inc. (Roche subsidiary)
    • 15.2.3. Illumina, Inc.
    • 15.2.4. GRAIL, Inc. (subsidiary of Illumina)
    • 15.2.5. Bio-Rad Laboratories, Inc.
    • 15.2.6. Exact Sciences Corporation
    • 15.2.7. Thermo Fisher Scientific Inc.
    • 15.2.8. Natera, Inc.
    • 15.2.9. Freenome Holdings, Inc.
    • 15.2.10. QIAGEN N.V.
    • 15.2.11. Lucence Diagnostics
    • 15.2.12. Inivata Ltd. (NeoGenomics subsidiary)
    • 15.2.13. Angle plc
    • 15.2.14. Sysmex Corporation
    • 15.2.15. Biocept, Inc.
    • 15.2.16. Oncocyte Corporation
    • 15.2.17. Personal Genome Diagnostics (PGDx)
    • 15.2.18. Chronix Biomedical
    • 15.2.19. Epic Sciences, Inc.
    • 15.2.20. Cynvenio Biosystems, Inc.
    • 15.2.21. Others

16. 360 Degree Analyst View

17. Appendix

  • 17.1. Research Methodology
  • 17.2. References
  • 17.3. Abbreviations
  • 17.4. Disclaimer
  • 17.5. Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제